Related Experiment Video
Updated: May 14, 2026
Laser Ablation of the Zebrafish Pronephros to Study Renal Epithelial Regeneration
Published on: August 29, 2011
Laser therapy in metabolic syndrome-related kidney injury
Alvaro C Ucero1, Bettina Sabban, Alberto Benito-Martin
1IIS-FundacionJimenezDiaz, Madrid, Spain.
Abstract:
Metabolic syndrome is characterized by hyperglycemia, hypertension, dyslipidemia and obesity. Diabetes and hypertension are the main causes of chronic end-stage kidney disease in humans. Chronic kidney disease is characterized by kidney inflammation and eventual development of kidney fibrosis. Low-level laser (or light) therapy (LLLT) can be used to relieve pain associated with some inflammatory diseases due to photochemical effects. Despite the known contribution of inflammation to metabolic syndrome and kidney disease, there is scarce information on the potential therapeutic use of LLLT in renal disease. The aim of this randomized, placebo-controlled study was to test the hypothesis that LLLT could modulate chronic kidney injury. Rats with nephropathy, hypertension, hyperlipidemia and type II diabetes (strain ZSF1) were subjected to three different conditions of LLLT or sham treatment for 8 weeks, and then sacrificed 10 weeks later. The main findings of this study are that the LLLT-treated rats had lower blood pressure after treatment and a better preserved glomerular filtration rate with less interstitial fibrosis upon euthanasia at the end of follow-up. This initial proof-of-concept study suggests that LLLT may modulate chronic kidney disease progression, providing a painless, noninvasive, therapeutic strategy, which should be further evaluated.
Insights
Low-level laser therapy (LLLT) may help manage chronic kidney disease progression. This study found LLLT reduced blood pressure and kidney damage in diabetic rats, suggesting a potential noninvasive treatment.
Area of Science:
- Nephrology
- Biomedical Engineering
- Photomedicine
Background:
- Metabolic syndrome, characterized by hyperglycemia, hypertension, dyslipidemia, and obesity, contributes to chronic kidney disease (CKD).
- Inflammation and fibrosis are key pathological features of CKD, a leading cause of end-stage renal disease.
- Low-level laser therapy (LLLT) has demonstrated anti-inflammatory effects, but its role in renal disease is under-explored.
Purpose of the Study:
- To investigate the potential therapeutic effects of LLLT on chronic kidney injury in a rat model of metabolic syndrome.
- To test the hypothesis that LLLT can modulate the progression of diabetic nephropathy, hypertension, and hyperlipidemia.
Main Methods:
- A randomized, placebo-controlled study involving ZSF1 rats with induced nephropathy, hypertension, hyperlipidemia, and type II diabetes.
- LLLT or sham treatment was administered for 8 weeks, with follow-up assessments 10 weeks post-treatment.
- Histopathological analysis and glomerular filtration rate (GFR) measurements were used to evaluate kidney injury and fibrosis.
Main Results:
- LLLT-treated rats exhibited significantly lower blood pressure post-treatment compared to controls.
- A better preserved glomerular filtration rate was observed in the LLLT group at the end of the follow-up period.
- Reduced interstitial fibrosis in the kidneys of LLLT-treated rats indicated a protective effect against chronic kidney injury.
Conclusions:
- LLLT demonstrates potential as a noninvasive therapeutic strategy to modulate the progression of chronic kidney disease.
- Further research is warranted to validate these findings and explore LLLT's clinical application in renal disease management.
- LLLT offers a painless approach for potentially slowing down kidney fibrosis and preserving kidney function.
